Sign in
TerminatedPhase 1/2

To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma

Key facts

Who runs it
Incyte Corporation
Where
Cincinnati, Detroit, Houston, Miami, Nashville, New Orleans, Palo Alto, and Sarasota, United StatesSee the 8 sitesAlso in 2 other countries, 7 sites
Status
Terminated
Phase
Phase 1/2
People taking part
22 people enrolled
Started
19 Aug 2021
Ended
15 Aug 2024
Type of study
Interventional
Treatments tested
  • INCB000928
Record updated
22 October 2025
Why it stopped
Strategic Business Decision

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 17 criteriaShow less

Who can take part

  • Agreement to avoid pregnancy or fathering children
  • Participants who are transfusion-dependent or present with symptomatic anemia; For MDS participants:
  • Ineligible to receive or have not responded to available therapies for anemia such as ESAs or lenalidomide
  • Not requiring cytoreductive therapy other than hydroxyurea
  • BM and peripheral blood myeloblast count < 10%
  • Histologically confirmed diagnosis of the MDS, CMML and unclassifiable MDS/MPN overlap syndromes; For MM participants:
  • Histologically confirmed diagnosis of MM
  • After failure of available standard treatments such as alkylating agents, glucocorticoids, immunomodulatory drugs (lenalidomide,pomalidomide, or thalidomide), proteasome inhibitors (bortezomib or carfilzomib), and daratumumab

Who cannot take part

  • Any prior allogeneic stem cell transplantation or a candidate for such transplantation
  • Any major surgery within 28 days before the first dose of study drug
  • Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, or antibody or hypomethylating agent to treat the participant's disease within 5 half-lives or 28 days (whichever is shorter) before the first dose of study drug
  • Undergoing treatment with another investigational medication or having been treated with an investigational medication within 28 days before the first dose of study drug. -Undergoing treatment with ESAs, granulocyte colony-stimulating factor or granulocyte/macrophage colony-stimulating factor, romiplostin, or eltrombopag at any time within 28 days before the first dose of study drug
  • Undergoing treatment with a strong or potent inhibitor or inducer of CYP3A4/5 within 28 days or 5 half-lives (whichever is longer) before the first dose of study drug or expected to receive such treatment during the study
  • History of clinically significant or uncontrolled cardiac disease
  • Presence of chronic or current active infectious disease requiring systemic antibiotic, antifungal, or antiviral treatment
  • Diagnosis of chronic liver disease
  • History or presence of an abnormal ECG that, in the investigator's opinion, is clinically Meaningful

Where in United States

Also in 2 other countries, 7 sites

  • University of CincinnatiCincinnati, United States
  • Barbara Ann Karmanos Cancer HospitalDetroit, United States
  • MD Anderson Cancer CenterHouston, United States
  • University of MiamiMiami, United States
  • Vanderbilt University Medical CenterNashville, United States
  • Tulane Comprehensive Cancer CenterNew Orleans, United States
  • Stanford Cancer CenterPalo Alto, United States
  • Florida Cancer SpecialistsSarasota, United States

About the trial

What the trial wants to find out

This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

The group in the trial

  • INCB000928Treatment being tested

    INCB000928 will be administered in participants with MDS or MM who are transfusion-dependent or present with symptomatic anemia.

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
A Phase 1/2, Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy in Participants With Anemia Due to Myelodysplastic Syndromes or Multiple Myeloma
Record updated
22 October 2025